Loading…
Addex Therapeutics Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ADXN.
▼ -97.7% over 5Y.
today you would have $20.26▼ -98.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $7.72 | $7.00 | $6.05 | $12.60 | |
| P/E | — | — | 0.8x | — | — |
| P/S | 1193.4x | 30374.9x | 1703.5x | 357.2x | 683.3x |
| P/B | 194.4x | 191.0x | 71.1x | 503.0x | 197.8x |
| EPS | -$7.20 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MLECMoolec Science SA | $6.80 | — | 9.7x | — | — | $4.94M |
| BRTXBioRestorative Therapies, Inc. | $0.20 | — | 1.7x | — | -241.14% | $5.07M |
| PCSAProcessa Pharmaceuticals, Inc. | $1.84 | 2.8x | — | — | -464.20% | $5.14M |
| AMIXAutonomix Medical, Inc. | $5.32 |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Company description provided by Yahoo Finance.
| $8.40 |
| -$16.80 |
| -$55.20 |
| Profit margin | -1058.52% | -22448.44% | 1746.04% | -654.47% | -1462.57% |
| ROE | -282.31% | -141.15% | 72.91% | -921.57% | -423.46% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.9x |
| — |
| -315.99% |
| $5.17M |
| POASPHAOS TECHNOLOGY HOLDINGS (CAYMAN) Ltd | $0.17 | — | — | — | — | $5.21M |
| VVOSVivos Therapeutics, Inc. | $0.22 | — | — | — | -8585.26% | $4.52M |